Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Subthalamic nucleus stimulation impairs motivation: Implication for apathy in Parkinson's disease.

Vachez Y, Carcenac C, Magnard R, Kerkerian-Le Goff L, Salin P, Savasta M, Carnicella S, Boulet S.

Mov Disord. 2020 Jan 13. doi: 10.1002/mds.27953. [Epub ahead of print]

PMID:
31930749
2.

Mapping Chemical Elements and Iron Oxidation States in the Substantia Nigra of 6-Hydroxydopamine Lesioned Rats Using Correlative Immunohistochemistry With Proton and Synchrotron Micro-Analysis.

Carmona A, Roudeau S, Perrin L, Carcenac C, Vantelon D, Savasta M, Ortega R.

Front Neurosci. 2019 Sep 26;13:1014. doi: 10.3389/fnins.2019.01014. eCollection 2019.

3.

DREADDs: The Power of the Lock, the Weakness of the Key. Favoring the Pursuit of Specific Conditions Rather than Specific Ligands.

Goutaudier R, Coizet V, Carcenac C, Carnicella S.

eNeuro. 2019 Oct 14;6(5). pii: ENEURO.0171-19.2019. doi: 10.1523/ENEURO.0171-19.2019. Print 2019 Sep/Oct. No abstract available.

4.

Nigrostriatal Dopaminergic Denervation Does Not Promote Impulsive Choice in the Rat: Implication for Impulse Control Disorders in Parkinson's Disease.

Magnard R, Vachez Y, Carcenac C, Boulet S, Houeto JL, Savasta M, Belin D, Carnicella S.

Front Behav Neurosci. 2018 Dec 13;12:312. doi: 10.3389/fnbeh.2018.00312. eCollection 2018.

5.

GLS1 Mutant Mice Display Moderate Alterations of Hippocampal Glutamatergic Neurotransmission Associated with Specific Adaptive Behavioral Changes.

Dutar P, Tolle V, Kervern M, Carcenac C, Carola V, Gross C, Savasta M, Darmon M, Masson J.

Neuroscience. 2019 Jan 1;396:175-186. doi: 10.1016/j.neuroscience.2018.11.022. Epub 2018 Nov 23.

PMID:
30472430
6.

[Motivation and apathy in Parkinson's disease: implication of dopaminergic D3 receptors].

Favier M, Carcenac C, Savasta M, Carnicella S.

Med Sci (Paris). 2017 Oct;33(10):822-824. doi: 10.1051/medsci/20173310004. Epub 2017 Oct 10. French. No abstract available.

7.

Organization of the Anterior Limb of the Internal Capsule in the Rat.

Coizet V, Heilbronner SR, Carcenac C, Mailly P, Lehman JF, Savasta M, David O, Deniau JM, Groenewegen HJ, Haber SN.

J Neurosci. 2017 Mar 8;37(10):2539-2554. doi: 10.1523/JNEUROSCI.3304-16.2017. Epub 2017 Feb 3.

8.

Implication of dorsostriatal D3 receptors in motivational processes: a potential target for neuropsychiatric symptoms in Parkinson's disease.

Favier M, Carcenac C, Drui G, Vachez Y, Boulet S, Savasta M, Carnicella S.

Sci Rep. 2017 Jan 30;7:41589. doi: 10.1038/srep41589.

9.

What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?

Magnard R, Vachez Y, Carcenac C, Krack P, David O, Savasta M, Boulet S, Carnicella S.

Transl Psychiatry. 2016 Mar 8;6:e753. doi: 10.1038/tp.2016.17. Review.

10.

Chronic Intermittent Hypoxia Induces Chronic Low-Grade Neuroinflammation in the Dorsal Hippocampus of Mice.

Sapin E, Peyron C, Roche F, Gay N, Carcenac C, Savasta M, Levy P, Dematteis M.

Sleep. 2015 Oct 1;38(10):1537-46. doi: 10.5665/sleep.5042.

11.

Subthalamic deep brain stimulation differently alters striatal dopaminergic receptor levels in rats.

Carcenac C, Favier M, Vachez Y, Lacombe E, Carnicella S, Savasta M, Boulet S.

Mov Disord. 2015 Nov;30(13):1739-49. doi: 10.1002/mds.26146. Epub 2015 Jan 14.

PMID:
25588931
12.

Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.

Carnicella S, Drui G, Boulet S, Carcenac C, Favier M, Duran T, Savasta M.

Transl Psychiatry. 2014 Jun 17;4:e401. doi: 10.1038/tp.2014.43.

13.

Pramipexole reverses Parkinson's disease-related motivational deficits in rats.

Favier M, Duran T, Carcenac C, Drui G, Savasta M, Carnicella S.

Mov Disord. 2014 Jun;29(7):912-20. doi: 10.1002/mds.25837. Epub 2014 Feb 11.

PMID:
24515412
14.

High-frequency stimulation of the subthalamic nucleus modifies the expression of vesicular glutamate transporters in basal ganglia in a rat model of Parkinson's disease.

Favier M, Carcenac C, Drui G, Boulet S, El Mestikawy S, Savasta M.

BMC Neurosci. 2013 Dec 5;14:152. doi: 10.1186/1471-2202-14-152.

15.

Enhanced visual responses in the superior colliculus and subthalamic nucleus in an animal model of Parkinson's disease.

Rolland M, Carcenac C, Overton PG, Savasta M, Coizet V.

Neuroscience. 2013 Nov 12;252:277-88. doi: 10.1016/j.neuroscience.2013.07.047. Epub 2013 Jul 31.

PMID:
23916713
16.

Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease.

Drui G, Carnicella S, Carcenac C, Favier M, Bertrand A, Boulet S, Savasta M.

Mol Psychiatry. 2014 Mar;19(3):358-67. doi: 10.1038/mp.2013.3. Epub 2013 Feb 12.

17.

Mitochondrial permeability transition pore inhibitors prevent ethanol-induced neuronal death in mice.

Lamarche F, Carcenac C, Gonthier B, Cottet-Rousselle C, Chauvin C, Barret L, Leverve X, Savasta M, Fontaine E.

Chem Res Toxicol. 2013 Jan 18;26(1):78-88. doi: 10.1021/tx300395w. Epub 2013 Jan 7.

PMID:
23268549
18.

Does MPTP intoxication in mice induce metabolite changes in the nucleus accumbens? A ¹H nuclear MRS study.

Chassain C, Bielicki G, Carcenac C, Ronsin AC, Renou JP, Savasta M, Durif F.

NMR Biomed. 2013 Mar;26(3):336-47. doi: 10.1002/nbm.2853. Epub 2012 Oct 12.

PMID:
23059905
19.

Discovering new bioactive neuropeptides in the striatum secretome using in vivo microdialysis and versatile proteomics.

Bernay B, Gaillard MC, Guryca V, Emadali A, Kuhn L, Bertrand A, Detraz I, Carcenac C, Savasta M, Brouillet E, Garin J, Elalouf JM.

Mol Cell Proteomics. 2009 May;8(5):946-58. doi: 10.1074/mcp.M800501-MCP200. Epub 2009 Jan 21.

20.

Development of a sialic acid-containing hydrogel of poly[N-(2-hydroxypropyl) methacrylamide]: characterization and implantation study.

Woerly S, Fort S, Pignot-Paintrand I, Cottet C, Carcenac C, Savasta M.

Biomacromolecules. 2008 Sep;9(9):2329-37. doi: 10.1021/bm800234r. Epub 2008 Aug 21.

PMID:
18715030
21.

High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats.

Lacombe E, Carcenac C, Boulet S, Feuerstein C, Bertrand A, Poupard A, Savasta M.

Eur J Neurosci. 2007 Sep;26(6):1670-80. Epub 2007 Sep 6.

22.

Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulata.

Boulet S, Lacombe E, Carcenac C, Feuerstein C, Sgambato-Faure V, Poupard A, Savasta M.

J Neurosci. 2006 Oct 18;26(42):10768-76.

23.

Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.

Brizard M, Carcenac C, Bemelmans AP, Feuerstein C, Mallet J, Savasta M.

Neurobiol Dis. 2006 Jan;21(1):90-101. Epub 2005 Aug 9.

PMID:
16084732
24.
25.

Neurochemical mechanisms induced by high frequency stimulation of the subthalamic nucleus: increase of extracellular striatal glutamate and GABA in normal and hemiparkinsonian rats.

Bruet N, Windels F, Carcenac C, Feuerstein C, Bertrand A, Poupard A, Savasta M.

J Neuropathol Exp Neurol. 2003 Dec;62(12):1228-40.

PMID:
14692699
26.

Hindlimb-suspension and spaceflight both alter cGMP levels in rat choroid plexus.

Carcenac C, Herbute S, Masseguin C, Mani-Ponset L, Maurel D, Briggs R, Guell A, Gabrion JB.

J Gravit Physiol. 1999 Oct;6(2):17-24.

PMID:
11543082
27.

Altered gravity downregulates aquaporin-1 protein expression in choroid plexus.

Masseguin C, Corcoran M, Carcenac C, Daunton NG, Güell A, Verkman AS, Gabrion J.

J Appl Physiol (1985). 2000 Mar;88(3):843-50.

Supplemental Content

Loading ...
Support Center